ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1252

Association of Paraoxonase 1 Gene Polymorphisms and Enzyme Activity with Carotid Plaque in Rheumatoid Arthritis

Christina Charles-Schoeman1, Yuen Yin Lee1, Veena K. Ranganath1, John FitzGerald1, Mihaela B. Taylor2, Maureen A. McMahon1, David Elashoff3 and Srinivasa T. Reddy4, 1University of California, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, CA, 3Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, 4Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, Cholesterol and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Paraoxonase 1 (PON1) is a high density lipoprotein (HDL) associated enzyme, which promotes the anti-oxidant and anti-inflammatory properties of HDL.  PON1 polymorphisms and enzyme activity have previously been associated with cardiovascular (CV) events in the general population. Since abnormal HDL function has been proposed to contribute to CV risk in patients with rheumatoid arthritis (RA), the current work investigated the relationship of genetic and biochemical determinants of PON1 activity with carotid plaque as a surrogate marker of CV risk in RA patients. 

Methods:

PON1 activity, PON1 genotype (for the functional polymorphism at position 192), and carotid plaque presence were determined in 168 patients with RA.  Fasting blood was collected for lipoprotein analysis, and PON1 activity was measured using paraoxon as the substrate.  Genotyping for the PON1 Q192R polymorphism (SNP rs662) was done for all patients as described previously (Bhattacharyya et al. JAMA 2008).  Lipoprotein cholesterol levels were measured by standard methods and traditional cardiovascular risk factors, medication use, and RA disease characteristics were assessed for all patients.

Results:

The PON1 genotype demonstrated a significant dose dependent association with PON1 activity (RR192 > QR192 > QQ192) (p<0.001). Compared to patients with either the PON1 QQ192 or QR192 genotype, patients with the RR192 genotype demonstrated decreased risk of carotid plaque in multivariate analysis controlling for traditional CV risk factors, high-sensitivity C-reactive protein levels, prednisone use, and cholesterol lowering medication use (p<0.05).  Separate multivariate logistic regression analysis controlling for the above factors also revealed a significant association of plasma PON1 activity with carotid plaque in RA patients.  Lower plasma PON1 activity was associated with increased risk of carotid plaque (p <0.05).

Conclusion:

The current work suggests a relationship between the genetic determinants and activity of PON1 with cardiovascular risk in RA patients as assessed by the presence or absence of carotid plaque.  Further CV outcome studies may be warranted to determine if PON1 is a useful biomarker of CV risk in patients with RA.


Disclosure:

C. Charles-Schoeman,
None;

Y. Y. Lee,
None;

V. K. Ranganath,
None;

J. FitzGerald,
None;

M. B. Taylor,
None;

M. A. McMahon,
None;

D. Elashoff,
None;

S. T. Reddy,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-paraoxonase-1-gene-polymorphisms-and-enzyme-activity-with-carotid-plaque-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology